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Abstract
Rationale: Existing data on the effect of treatment of latent tuberculosis infection (LTBI) on T-cell
responses to Mycobacterium tuberculosis (MTB)-specific antigens are contradictory. Differences in
technical aspects of the assays used to detect this response and populations studied might explain
some of these discrepancies. In an attempt to find surrogate markers of the effect of LTBI
treatment, it would be important to determine whether, among contacts of patients with
contagious tuberculosis, therapy for LTBI could cause changes in MTB-specific immune responses
to a variety of RD1-antigens.
Methods and results: In a longitudinal study, 44 tuberculin skin test+ recent contacts were
followed over a 6-month period and divided according to previous exposure to MTB and LTBI
treatment. The following tests which evaluate IFN-gamma responses to RD1 antigens were
performed: QuantiFERON TB Gold, RD1 intact protein- and selected peptide-based assays.
Among the 24 contacts without previous exposure that completed therapy, we showed a
significant decrease of IFN-gamma response in all tests employed. The response to RD1 selected
peptides was found to be more markedly decreased compared to that to other RD1 antigens.
Conversely, no significant changes in the response to RD1 reagents were found in 9 treated
subjects with a known previous exposure to MTB and in 11 untreated controls.
Conclusion:  These data suggest that the effect of INH prophylaxis on RD1-specific T-cell
responses may be different based on the population of subjects enrolled (recent infection versus
re-infection) and, to a minor extent, on the reagents used.
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Background
According to the World health Organization, one-third of
the world's population harbours Mycobacterium tuberculo-
sis (MTB) in an asymptomatic, latent form (latent tuber-
culosis [TB] infection [LTBI]) but retains a lifelong risk of
future disease. The control and elimination process of the
global TB epidemic could be enhanced by identification
and treatment of individuals with LTBI, in particular of
individuals who recently acquired the infection as the risk
of developing active disease is higher in the first 2 years
after exposure [1,2].
Until recently, the tuberculin skin test (TST) has been the
only tool used to detect LTBI, but this test is flawed oper-
ationally and in terms of specificity and sensitivity [3].
Lately, in vitro assays have been made available that detect
interferon (IFN)-gamma responses to a combination of
antigens (early secreted antigenic target 6 [ESAT-6] and
culture filtrate protein 10 [CFP-10]) encoded by the RD1
(region of difference) genomic segment, which is absent
from most non-pathogenic mycobacteria, including Bacil-
lus Calmette Guerin (BCG) [3-5]. Available evidence sug-
gests that these tests may be more accurate than TST in the
diagnosis of MTB infection, either latent or active, and two
tests have been approved for the diagnosis of TB [6-13].
Moreover, results of our previous studies suggest that IFN-
gamma response to multiepitopic peptides from ESAT-6
and CFP-10 (RD1) proteins selected by computational
analysis is associated with active TB disease [14-18].
Several unresolved issues remain on the potential clinical
use of IFN-gamma release assays [6,7], and one area of
controversy is whether these immune assays can be used
for monitoring the response to TB treatment. Conflicting
results are available on the effect of therapy for active TB
disease on RD1 responses with reduced or increased
responses during treatment [15,19-21]. The existing data
on the effect of LTBI treatment on T-cell responses are also
contradictory [22-25]. One study shows declining
responses [22], whereas others have shown unchanging
[23], fluctuating or increasing responses during therapy
[24,25]. It is plausible that variations in technical aspects
of assay performance such as antigens used (proteins vs.
peptides), assay formats (ELISA vs. ELISPOT), time of
observation (during therapy or after therapy completion),
and population studied (recent versus old contacts) might
explain some of these discrepancies.
Consequently, we reasoned that in an attempt to find sur-
rogate markers of the effect of LTBI therapy, it would be
important to determine in a prospective study whether, in
a defined population of recent healthy close contacts of
patients with pulmonary TB, isoniazid (INH) for LTBI
treatment could cause changes in MTB-specific immune
responses to a variety of RD1 antigens, such as the RD1
overlapping peptides of the QuantiFERON TB-Gold assay
(QTF-G), RD1 intact proteins and selected peptides.
Moreover to evaluate whether or not a previous infection
could influence such response we included a control
group composed of subjects with a known past exposure
to MTB.
Materials and methods
Patient population and study design
In a one-year period we enrolled close contacts of infec-
tious TB patients in 2 outpatient services in Rome, Italy
(Presidio interzonale di pneumologia ASL Roma E, and
National Institute for Infectious Diseases "L. Spallan-
zani"). We included in the present analysis individuals
who tested TST+, who consented to provide a blood sam-
ple at the time of initial screening (time 1) and on subse-
quent occasions within the following six months (after 1–
2 months: time 2; after 6 months: time 3), and who were
symptom-free and with normal chest radiographs [chest
radiographs were read by one board-certified radiologist
and at least one infectious disease specialist or pneumol-
ogist (DG, GA, DD)] on initial screening. Patients were
not included in the analysis if they were at risk for Human
Immunodeficiency Virus infection (HIV), or if they
reported having had active TB in the past, or having previ-
ously received treatment for LTBI. Upon enrolment demo-
graphic and epidemiological information were collected,
including information about BCG vaccination. Data were
collected by the physician through a structured question-
naire.
Individuals included in the analysis were classified into
four groups based on the history of past exposure to a
patient with contagious TB, and on whether or not they
were receiving treatment for LTBI. The study was approved
by the ethics committee at our institution and all enrolled
individuals provided written informed consent prior to
screening procedures, as did the parents of the children
included in the study.
TST
TST was administered by the Mantoux procedure using 5
IU of purified protein derivative (PPD) (Chiron, Siena,
Italy). Results were read after 72 hours. Induration of at
least 5 mm was considered a positive response [26,27].
Whole blood ELISA (WBE) based on RD1 selected peptides 
and proteins
Selection of Human Leukocyte Aplotype (HLA)-class II-
restricted epitopes of ESAT-6 and CFP-10 proteins was
performed by quantitative implemented HLA peptide-
binding motifs analysis [14]. Peptides were synthesized as
free amino acid termini using Fmoc chemistry (ABI, Ber-
gamo, Italy). The following lyophilized peptides, diluted
in DMSO at stock concentrations of 10 mg/mL, were usedRespiratory Research 2007, 8:5 http://respiratory-research.com/content/8/1/5
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and stored at -80°C: ESAT-6 6–28, 67–79 and CFP-10 18–31, 41–
68, 74–86.
All samples were analyzed by WBE assays, as previously
described [16]. Briefly, 0.5 ml per well of heparinized
blood was seeded in a 48-well plate and treated with RD1
intact proteins at 0.2 µg/ml (Lionex, Braunschweig, Ger-
many), RD1 selected peptides (pool of CFP-10 peptides at
6 µg/ml; pool of ESAT-6 peptides at 10 µg/ml), purified
protein derivative (PPD) at 5 µg/ml (batch RT 47, Staten
Serum Institut, Copenhagen, Denmark) and Phytohe-
magglutinin (PHA) at 5 µg/ml (Sigma, St Louis, MO,
USA). Samples were then incubated for 24 hours at 37°C.
IFN-gamma levels in culture supernatants were assessed
by a commercially available kit (QuantiFERON-CMI kit,
Cellestis Limited, Carnegie, Victoria, Australia). For IFN-
gamma values above 10 IU/ml serial dilutions of plasma
were performed.
Results are presented as IU/ml for ELISA after subtraction
of the appropriate control according to the described cri-
teria [16]. Cut-off values were determined by constructing
a Receiver Operator Characteristic (ROC) curve by means
of LABROC-1 software and were 0.7 IU/mL for all stimuli.
Commercially available assay
QTF-G (Cellestis Limited, Carnegie, Victoria, Australia)
was performed and its results were scored as indicated by
the manufacturer (cut-off value for a positive test was 0.35
IU/ml). For IFN-gamma values above 10 IU/ml serial
dilutions of plasma were performed.
Statistical analysis
The main outcome of the study was the effect of treatment
in terms of IFN-gamma production in response to anti-
genic stimulation in the QTF-G and WBE, expressed as
dichotomous (positive/negative) and continuous (IU/
mL) measures. IFN-gamma mean ± SE was calculated. The
Mann-Whitney U test was used to compare continuous
variables, and Chi square or McNemar tests were used for
categorical variables. Analysis was carried out with SPSS v
14 for Windows (SPSS Italia srl, Bologna, Italy).
Results
We prospectively recruited 238 contacts of patients with
sputum smear positive pulmonary TB. Among them, 146
resulted TST+ and 44 of them accepted to be followed over
time and were included in the analysis. The study group
was divided into those who did not report having had any
previous exposure to a smear positive TB case (30), and
those who did (14). Among the former group, 6 patients
did not receive therapy on the grounds that two were con-
tacts of a patient with multidrug-resistant TB, two had
chronic hepatitis C and two refused treatment; five sub-
jects belonging to the latter group decided to not undergo
INH therapy (figure 1).
Characteristics of individuals enrolled, divided according
to previous TB exposure and LTBI treatment are shown in
table 1. The group of those without a previous exposure
under INH therapy had a significantly younger age (p <
0.001) compared to the other groups. No significant dif-
ferences among the four groups were observed for the
characteristics considered.
Time course of MTB-specific immune response in recently 
exposed contacts
Untreated subjects
In all 6 untreated individuals without a known exposure
to MTB IFN-gamma production did not significantly
change over time for any of the stimuli and tests used
(PPD, QTF-G, RD1 intact proteins and peptides) (table 2).
Similar data were obtained in 5 individuals with a
reported TB exposure in the past re-exposed recently to
MTB that refused INH therapy (table 3).
INH-treated subjects
The IFN-gamma response to PPD, QTF-G, RD1 intact pro-
teins and selected peptides of the 24 TST+ individuals that
started therapy, and that did not report a previous expo-
sure to MTB in the past, is shown in Figure 2 and table 2.
IFN-gamma production in response to PPD was detected
in all the individuals studied (24/24, 100%) and did not
significantly change over time (Figure 2A and table 2).
In the QTF-G assay, 5 of the 24 contacts did not respond
throughout the study period. In the 19 individuals who
did show a response, IFN-gamma significantly decreased
at time 2 (p = 0.03 vs. time 1) with a 34% reduction over
baseline, and a 70% reduction at time 3 (p = 0.0001 vs.
time 1) (Figure 2B and table 2). The proportion of positive
responses to QTF-G at time 2 (18/19) and at time 3 (18/
19) did not differ significantly from that observed at time
1.
Responses to RD1 intact proteins at baseline were nega-
tive in 6 of the 24 contacts and remained negative over
time. In the 18 responders a significant decrease in IFN-
gamma production was noticed: 57% reduction over
baseline at time 2, (p = 0.001 vs. time 1) and 79% reduc-
tion at time 3 (p = 0.0002 vs. time 1) (Figure 2C and table
2). The percentage of positive responses at time 2 was
77% (14/18) (p > 0.5 vs. time 1) and 61% (11/18) at the
end of therapy (p < 0.007 vs. time 1).
Responses to RD1 selected peptides were noticed in 15/24
subjects, while the remaining 9 were negative throughout
the study. The 15 responders showed a significantRespiratory Research 2007, 8:5 http://respiratory-research.com/content/8/1/5
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decrease of IFN-gamma production at time 2 (p = 0.005
vs. time 1) with a 63% reduction over baseline, and a 91%
reduction at time 3 (p = 0.0005 vs. time 1), as shown in
figure 2D and table 2. The percentage of positive
responses to RD1 selected peptides was 73% (11/15) at
time 2 (p > 0.5 vs. time 1) and 47% (7/15) at the end of
treatment (p < 0.002 vs. time 1).
Among these same individuals TST cuticonversion was
observed in 9/24. However no differences were observed
in the trends of RD1 responses when the results from
these individuals were compared with those from the
remaining 15 subjects in whom a cuticonversion was not
observed (data not shown).
It is interesting to note that in the group of the 9 individ-
uals that reported an exposure to MTB in the past and
started INH therapy at the time of the present study, the
IFN-gamma response to PPD, QTF-G, RD1 intact proteins
and selected peptides did not significantly change over
time (Figure 3 and table 3). In particular, all 9 individuals
responded to PPD, QTF-G, RD1 intact proteins whereas
only 6 responded to the selected peptides. Percentages of
positive responses remained stable over time for all the
stimuli used.
Discussion
In this pilot study, we show that INH preventive therapy
is associated with a significant decrease of the in vitro RD1
responses in individuals with LTBI with a recent exposure
to MTB, who did not report any exposure in the past. This
decrease was observed, although to a different extent, with
all RD1 antigen reagents used. It is important to note that
the trend of decrease of the test using RD1 selected pep-
Study flow diagram Figure 1
Study flow diagram. PPD: purified protein derivative; RD: region of difference; QTF-G: QuantiFERON TB Gold; INH: isoni-
azid; TST: tuberculin skin test.Respiratory Research 2007, 8:5 http://respiratory-research.com/content/8/1/5
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tides was particularly marked after 1–2 months of therapy
and that the response of the majority became undetecta-
ble after six months, while the response to the other RD1
products (overlapping peptides of the QTF-G and RD1
intact proteins) decreased more slowly and fewer negative
results were observed after six months of therapy. These
differences may be related to the amount and the compo-
sition of epitopes covered by the peptides and intact pro-
teins. For example, the peptides employed in the QTF-G
cover the whole CFP-10 and ESAT-6 intact proteins (in
addition to having a peptide from TB7.7) [12] whereas the
peptides used in our assay are few and selected in order to
be highly immunogenic [14]. Based on our data, this oli-
goclonal response appears to be a sensitive tool to moni-
tor MTB replication as well as active TB disease, more so
than the polyclonal one against all RD1 epitopes. It is also
important to note that among all these recent contacts
nine did not respond at the first time of observation to
RD1 selected peptides. Five of them did not respond to
QTF-G either, and therefore it is likely that these subjects
were not infected with MTB, although they were TST+. Fur-
ther investigations are needed to clarify the meaning of
these differences. In contrast, no significant variation was
observed in individuals with LTBI who, in addition to a
recent exposure, had also a past exposure to contagious TB
patients. Altogether, these data suggest that RD1-based
assays may be a tool to monitor therapy-related changes
of MTB-specific immune responses not only in patients
Table 1: Epidemiological and demographic characteristics of TST+ contacts of pulmonary TB cases included in the study.
Characteristics No INH INH
No past exposure
N. 6
Past exposure
N. 5
No past exposure
N. 24
Past exposure
N. 9
Total
N.44
Median age (years) 35.5 49 21 52 30
Female gender N. (%) 1 (17) 3 (60) 16 (66) 6 (66) 26 (59)
Index cases, N. 5588 2 6
Country of birth, N. (%)
Italy 4 (66) 5 (100) 13 (54) 8 (89) 30 (68)
Abroad 2 (34) - 11 (46) 1 (11) 14 (32)
BCG vaccinated, N. (%) 2 (33) 1 (25) 11 (46) 1 (11) 18 (41)
TST-response (induration), N.(%)
5–10 mm 1 (16) - 7 (29) 1 (11) 9 (20)
11–15 mm 2 (33) 1 (20) 9 (37.) 1(11) 13 (30)
>15 mm 3 (50) 4 (80) 8 (33) 7 (78) 22 (50)
Table 2: TST+ subjects without a past MTB exposure: trends of RD1 test during follow up in the responders*
Group of subjects analysed Number of subjects
N (%)
Time 1
0 months
Time 2
1–2 months
Time 3
6 months
Time 2 vs time 1 Time 3 vs time 1
IFN-gamma (IU/ml)
No INH 6 (100)
PHA 6 (100) 9.9 ± 4.3 8.6 ± 4.1 12.1 ± 6.5 Ns Ns
PPD 6 (100) 27.4 ± 3.1 21.4 ± 4.9 23.5 ± 3.8 Ns Ns
QTF-G 6 (100) 21.1 ± 5.2 19.5 ± 7.2 20.2 ± 6.1 Ns Ns
RD1 proteins 6 (100) 16.1 ± 4.5 16.3 ± 7.2 7.3 ± 2.2 Ns Ns
RD1 peptides 6 (100) 7.5 ± 3.3 7.0 ± 4.7 5.7 ± 4 Ns Ns
INH therapy 24 (100)
PHA 24 (100) 14.7 ± 2.7 16.8 ± 3 14.8 ± 2.8 Ns Ns
PPD 24 (100) 17.6 ± 2.8 15.6 ± 2.7 14.1 ± 2.5 Ns Ns
QTF-G 19 (79) 17.5 ± 2.7 11.6 ± 2.5 5.2 ± 1.3 p = 0.03 p = 0.0001
RD1 proteins 18 (75) 12.5 ± 2.6 5.4 ± 1.4 2.6 ± 0.9 p = 0.001 p = 0.0002
RD1 peptides 15 (63) 9.2 ± 1.7 3.4 ± 0.9 0.9 ± 0.1 p = 0.005 p = 0.0005
*Responders are defined as those responding to the tests at baseline.
T1: time 1 (baseline); T2. time 2 (after 1–2 months INH therapy), T3: time 3 (after 6 months, at therapy completion). IFN: interferon; PHA: 
Phytohemagglutinin; PPD: purified protein derivative; RD: region of difference; QTF-G: QuantiFERON TB Gold; IFN: interferon; IU: international 
units. INH: isoniazid; ns: not statistically significant.Respiratory Research 2007, 8:5 http://respiratory-research.com/content/8/1/5
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with active disease, as previously demonstrated by us and
others [15,19-21], but also in individuals with a recently
acquired LTBI.
A few studies have been previously published on the effect
of LTBI therapy on T-cell responses. Decreasing responses
to CFP-10 overlapping peptides, and not to ESAT-6, were
found after INH therapy in recently exposed contacts [22]
that are comparable to the group of recent contacts evalu-
ated in the present study. However, we did not find differ-
ences in the responses to the reagents CFP-10 and ESAT-6
evaluated separately (either proteins or peptides, data not
shown). On the other hand, increasing and/or fluctuating
IFN-gamma responses were found by Ewer et al. in chil-
dren exposed for over 9 months to a case of pulmonary TB
that underwent therapy (INH and rifampicin) almost a
year after exposure [25]. Given the continuous exposure
over a considerable period of time described in that paper,
it is plausible that LTBI was already established at the time
of treatment, with the consequence of a different modula-
tion of T-cell responses compared to our study in which
treatment was rapidly started in those without a past con-
tact with MTB. In addition, in this study INH was used as
chemotherapy, whereas other studies reported INH plus
rifampicin [25] and it is unknown if different chemother-
apies may have a different impact on MTB antigen expo-
sure to the immune system [28]. Conversely Pai et al.
found unchanging IFN-gamma responses to QTF-G after
INH therapy in a population of health care workers
(HCW) in India [23]. These subjects, given their continu-
ous exposure to MTB, might have an immune response
similar to that of our group of re-infected individuals in
which no change of RD1 responses was observed over
time, and therefore these results are comparable to ours.
These data may indicate that the conflicting results found
in the literature may be due, at least in part, to the popu-
lation selected (recent infection vs. past infection with re-
exposure).
The reasons for the different effect of therapy in modulat-
ing RD1 responses in recently infected patients vs. those
potentially reinfected, observed in the present study, are
currently unclear. In several models of infectious diseases
it has been shown that the immune response is strictly
dependent on pathogen replication and antigenic load
[29-31]. In studies on in vitro IFN-gamma response to TB
antigens in particular, it has been hypothesized that short
incubation assays (as those used in this study) detect
responses of partially activated effector T cells that have
recently encountered antigens in vivo, and can therefore
rapidly release IFN-gamma when stimulated in vitro. This
suggests a correlation between the measure of this
response and antigen load [6,11,12]. All the contacts who
received INH in this study were exposed to an index TB
case who was infected by an INH-sensitive strain, and all
these contacts had good adherence to treatment as
assessed by interview. Therefore it can be hypothesized
that subjects treated early after recent infection may have
had a rapidly controlled infection owing to the combina-
tion of an effective treatment and an efficient immune
response, with a consequent decrease of the RD1-specific
effector cells. In contrast, it is likely that contacts with pre-
Table 3: TST+ subjects with a past MTB exposure: trends of RD1 test during follow up in the responders*
Group of subjects analysed Number of subjects
N (%)
Time 1
0 months
Time 2
1–2 months
Time 3
6 months
Time 2 vs. time 1 Time 3 vs. time 1
IFN-gamma (IU/ml)
No INH 5 (100)
PHA 5 (100) 14.2 ± 3.4 17.1 ± 4.5 17.5 ± 4.6 Ns Ns
PPD 5 (100) 31.4 ± 2.5 33 ± 3.4 29.3 ± 4.5 Ns Ns
QTF-G 5 (100) 16.4 ± 5.1 12.3 ± 4.4 16.3 ± 6.7 Ns Ns
RD1 proteins 5 (100) 11.8 ± 3.8 8.9 ± 3.2 13.5 ± 6.1 Ns Ns
RD1 peptides 5 (100) 6.1 ± 2 2.2 ± 0.5 4.6 ± 2 Ns Ns
INH therapy 9 (100)
PHA 9 (100) 17.7 ± 6 20.4 ± 4.4 17.8 ± 4.1 Ns Ns
PPD 9 (100) 19.6 ± 4.5 19.4 ± 4.7 24.2 ± 5.2 Ns Ns
QTF-G 9 (100) 15.2 ± 4 11.3 ± 4 9.4 ± 2.7 Ns Ns
RD1 proteins 9 (100) 6 ± 2 8.8 ± 3.3 11.9 ± 5.2 Ns Ns
RD1 peptides 6 (66) 4.4 ± 2.7 4.1 ± 1.4 7 ± 3 Ns Ns
*Responders are defined as those responding to the tests at baseline.
T1: time 1 (baseline); T2. time 2 (after 1–2 months INH therapy), T3: time 3 (after 6 months, at therapy completion). IFN: interferon; PHA: 
Phytohemagglutinin; PPD: purified protein derivative; RD: region of difference; QTF-G: QuantiFERON TB Gold; IFN: interferon; IU: international 
units. INH: isoniazid; ns: not statistically significant.Respiratory Research 2007, 8:5 http://respiratory-research.com/content/8/1/5
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vious untreated LTBI host different populations of myco-
bacteria, characterised by different growth rates: those
originating from the recent infection, which are actively
replicating and on which INH is effective, and those in a
dormant state that INH is not effective in killing [28]. This
pool of dormant bacilli may be the cause of the longer
persistence of the T cell response over time and also be
responsible for the generation and maintenance of a large
population of memory cells, similar to that obtained after
several boosts of vaccination; at the time of the present
study, reinfection may have caused a rapid and strong
effector/memory response caused by the expansion of this
pool of central memory cells [32]. However it is possible
that this response would decrease at later time points than
the 6 months of our study. Therefore, future investigations
are needed to evaluate the role of effector and memory T
cells on the modulation of this long lasting response not
only within, but also beyond the period of treatment.
Based on all these observations, although LTBI has been
proposed to be a static process [33], our data favour a
dynamic model of LTBI, whereby subpopulations of
actively replicating bacilli are controlled by the immune
response [18,22-25].
Some potential limitations of the present study should be
considered. Firstly, we were able to document only 9 cuti-
conversions among the 24 individuals who did not report
a previous exposure to MTB. This limit however is com-
A-D. INH-treated TST+ subjects without a past MTB exposure: time course of M.tuberculosis-specific immune response Figure 2
A-D. INH-treated TST+ subjects without a past MTB exposure: time course of M.tuberculosis-specific immune 
response. Responses to PPD, RD1 intact proteins, RD1 selected peptides and QTF-G in TST+ contacts that underwent INH 
therapy were evaluated over time at time 1 (baseline), time 2 (after 1–2 months of INH therapy), time 3 (therapy completion). 
Responses to PPD (A) were not significantly affected, unlike those to QTF-G (B), to RD1 intact proteins (C), and to RD1 
selected peptides (D), which were found to significantly change over time. PPD: purified protein derivative; RD: region of dif-
ference; QTF-G: QuantiFERON TB Gold; IFN: interferon; IU: international units.Respiratory Research 2007, 8:5 http://respiratory-research.com/content/8/1/5
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mon to previous studies [22,25], and it is important to
note that the risk of previous unknown exposures in these
individuals is very low because the subjects enrolled were
young (median age 21 years) and the majority were born
in Italy (68%) where the incidence of TB is low (8 per
100,000 inhabitants in 2004, including 39% of foreign-
born individuals) [34]. Secondly, TB exposure was
assessed by administering a questionnaire, and thus this
information may be affected by recall bias. Thirdly, INH
was not administered as directly observed therapy and
consequently the evaluation of adherence, performed by
patient interview, may have been imprecise. Lastly, gener-
alisation of our results may be limited by the fact that a
relatively low number of TST+ subjects were available for
follow-up, since many individuals refused further blood
drawing.
Conclusion
In conclusion, our preliminary data suggest the possibility
of using RD1 immune responses as surrogate markers of
efficacy during LTBI treatment. A larger study is needed to
better evaluate the difference in kinetics of the T-cell
response after exposure to MTB in those with an already
established LTBI vs. those recently infected.
A-D. INH-treated TST+ subjects with a past MTB exposure: time course of M.tuberculosis-specific immune response Figure 3
A-D. INH-treated TST+ subjects with a past MTB exposure: time course of M.tuberculosis-specific immune 
response. Responses to PPD (A), QTF-G (B), RD1 intact proteins (C), and RD1 selected peptides (D) in TST+ contacts that 
underwent INH therapy were evaluated over time at time 1 (baseline), time 2 (after 1–2 months of INH therapy), time 3 (ther-
apy completion) and no statistically significant changes were recorded. PPD: purified protein derivative; RD: region of differ-
ence; QTF-G: QuantiFERON TB Gold; IFN: interferon; IU: international units.Respiratory Research 2007, 8:5 http://respiratory-research.com/content/8/1/5
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• MTB: Mycobacterium tuberculosis
• PHA: Phytohemagglutinin
• PPD: purified protein derivative
• QFT-G: QuantiFERON TB Gold
• RD: region of difference
• RD1: CFP-10 and ESAT-6
• TST: tuberculin skin test
• TB: Tuberculosis
• WBE: whole blood ELISA
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